报价延迟最少15分钟:2026/10/18 20:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.74 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.75/-2.22
|
|
企业价值
898.17M
|
| 资产负债 |
|
每股账面净值
5.71
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
123.67M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC). |
